What is TRAW's health score?

Traws Pharma, Inc. (TRAW) has a TradeApes health score of 41 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is TRAW's estimated fair value?

Based on our 5-year discounted cash flow model, Traws Pharma, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is TRAW undervalued or overvalued?

Our model currently rates TRAW as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for TRAW... Refresh in a moment for the full analysis.

Traws Pharma, Inc. (TRAW)

Healthcare Inconclusive inconclusive weak

$1.37

Updated: 2026-06-06

TradeApes Score

Financial Strength

25 Stressed

Operating Trend

60 Healthy

Relative Value

40 Weak

Capital Allocation

30 Weak

Risk

50 Mixed

Key Findings

+ High ROIC — above 20%, excellent return on invested capital

Unlock Full Report →

− Excessive stock comp — SBC above 15% of revenue, wealth transfer to employees

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.